Roche Setback Is Big for Eli Lilly, Novo Nordisk Stock
Roche Setback Is Big for Eli Lilly, Novo Nordisk Stock as Obesity Drug Battle Ramps Up
The Switzerland-based pharmaceutical company has been trying to crack the weight-loss boom currently dominated by Eli Lilly and Novo Nordisk. Roche shares fell 2.8% in Zurich on T
Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now
Amgen is a decently valued stock that has an excellent business and also gives investors a way to potentially gain exposure to a lucrative weight loss market.
Eli Lilly, Novo Nordisk and other Big Pharmas back OAC’s ‘Your Weight Matters’ campaign challenge
Nonprofit group the Obesity Action Coalition (OAC) is running a new challenge as part of its “Your Weight Matters” campaign—and it’s got some big-name backers to help. | Nonprofit group the Obesity Action Coalition (OAC) is running a new challenge as part of its “Your Weight Matters” campaign—and it’s got some big-name backers to help.
How Novartis plans to thrive without competing directly with Eli Lilly in weight loss drug market
Novartis says it's not interested in joining weight-loss drugs frenzy. CEO Vas Narasimhan explained why today on CNBC's "Squawk Box Europe".
Healthy Returns: Eli Lilly could soon become the first $1 trillion health-care stock
Eli Lilly could be on its way to topping $1 trillion in market value. Meanwhile, Abbott launches its first over-the-counter continuous glucose monitor in U.S.
Novo Nordisk’s new weight-loss pill Amycretin beats Wegovy in early trial
The highly anticipated new obesity pill shows the potential for greater and faster weight loss than Wegovy. There is a new chapter in Big Pharma’s billion-dollar war on obesity, as Novo Nordisk and Eli Lilly battle it out over the latest blockbuster drugs.
Forget Eli Lilly and Novo Nordisk: This Could Be the Best Weight Loss Stock to Buy Right Now
If you want to invest in the fast-growing weight loss industry, going with stocks such as Eli Lilly or Novo Nordisk can seem like a great idea. They have leading weight loss products and possess ...
Roche falls while Novo, Lilly gain on weight-loss drug report
Roche (RHHBY) stock slid 5% Wednesday after Reuters reported that positive data released in July for Roche's obesity pill CT-996 was based on only six patients. Read more here.
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...
FierceBiotech13d
Lilly closes distance on Novo with another clutch of positive data on once-weekly insulin prospect
On the heels of an FDA rejection for its chief rival Novo Nordisk, Eli Lilly is gaining ground in the race to bring a ...
STAT7d
Eli Lilly releases new data on weekly insulin
Eli Lilly's new insulin data —Sanofi x Regeneron autoimmune drugs —Gilead's new AI partnership Get the full rundown here: ...
Vermont Business Magazine1d
Ahead of Novo Nordisk hearing, 250 clinicians demand affordable access to Ozempic and Wegovy
Novo Nordisk CEO Lars Jørgensen will testify about the high cost of Ozempic and Wegovy at an upcoming HELP Committee hearing on September 24th.
Morningstar13d
Eli Lilly's weekly insulin intensifies race with Novo Nordisk
Positive late-stage trial results come after Novo Nordisk's weekly insulin was rejected by FDA A pair of late-stage trials found that Eli Lilly & Co.'s experimental once-weekly insulin can ...